LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

Accueil・Liste d'Actions・Amarin Corp PLC ADR

Amarin Corp PLC ADR

Fermé

0.58

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.57

Max

0.59

Chiffres clés
By Trading Economics
Revenu	11M 1.5M
Ventes	11M 67M
BPA	0.01
Marge bénéficiaire	2.252
EBITDA	13M 237K

Recommandations
By TipRanks
Recommandations	Vente
Prévisions sur 12 Mois	+66.67 upside

Dividendes
By Dow Jones
Prochains Résultats	30 oct. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-11M 246M
Ouverture précédente	0.58
Clôture précédente	0.58

Score Technique

By Trading Central

Confiance

Bullish Evidence

0.5818 / 0.6095 Support & Résistance

Amarin Corp PLC ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 sept. 2024, 23:40 UTC

Actions en Tendance

Stocks to Watch: Intel, Netcapital, Microsoft

16 sept. 2024, 22:56 UTC

Acquisitions, Fusions, Rachats

Xero Bolsters Customer Insights With $70 Million Acquisition of Syft

16 sept. 2024, 19:21 UTC

Acquisitions, Fusions, Rachats

Vista Equity Partners, Blackstone Close to $8 Billion Buyout Deal for Smartsheet, Reuters Reports

16 sept. 2024, 22:47 UTC

Market Talk

Auckland International Airport's August Traffic Underwhelms -- Market Talk

16 sept. 2024, 22:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 sept. 2024, 22:47 UTC

Market Talk

Global Equities Roundup: Market Talk

16 sept. 2024, 22:41 UTC

Acquisitions, Fusions, Rachats

Xero Bolsters Customer Insights With $70 Mln Acquisition of Syft

16 sept. 2024, 22:37 UTC

Acquisitions, Fusions, Rachats

Santos to Own 36.5% of Bayu-Undan Following Sale, Purchase Deed

16 sept. 2024, 22:36 UTC

Acquisitions, Fusions, Rachats

Santos: Production Sharing Contract for Bayu-Undan to Cease at End-June 2026 or When Output Stops if Earlier

16 sept. 2024, 22:35 UTC

Acquisitions, Fusions, Rachats

Santos: Bayu-Undan JV Executes Sale, Purchase Deed to Transfer 16% Stake in Upstream Project to Timor GAP

16 sept. 2024, 22:34 UTC

Acquisitions, Fusions, Rachats

Xero: Syft's More Than 70 Employees Will Transition With Acquisition

16 sept. 2024, 22:31 UTC

Acquisitions, Fusions, Rachats

Xero: Syft Will Still Be Available as a Standalone Offering

16 sept. 2024, 22:30 UTC

Acquisitions, Fusions, Rachats

Xero: Syft Is Used in More Than 80 Countries

16 sept. 2024, 22:30 UTC

Acquisitions, Fusions, Rachats

Xero Expects to Complete Acquisition of Johannesburg-Based Syft in 3Q FY25

16 sept. 2024, 22:29 UTC

Acquisitions, Fusions, Rachats

Xero to Pay Balance in Earnouts, Restricted Stock Over Three Years

16 sept. 2024, 22:28 UTC

Acquisitions, Fusions, Rachats

Xero Will Pay US$40 Mln Up Front Including US$10 Mln in Shares

16 sept. 2024, 22:28 UTC

Acquisitions, Fusions, Rachats

Xero Will Embed Syft to Accelerate Insights, Analytics Offerings

16 sept. 2024, 22:27 UTC

Acquisitions, Fusions, Rachats

Xero: Syft Services Accountants, Bookkeepers, Small Businesses

16 sept. 2024, 22:27 UTC

Market Talk

Auckland Airport Raises More Equity Than Citi Expected -- Market Talk

16 sept. 2024, 22:26 UTC

Acquisitions, Fusions, Rachats

Xero: Syft Is a Cloud-Based Reporting, Insights, Analytics Platform

16 sept. 2024, 22:26 UTC

Acquisitions, Fusions, Rachats

Xero Acquiring Syft Analytics for Up to US$70 Million

16 sept. 2024, 22:08 UTC

Actualités

Microsoft Boosts Dividend, Authorizes Up to $60B of Buybacks

16 sept. 2024, 21:17 UTC

Actualités

Intel CEO Lays Out New Steps to Cut Costs and Bolster Chip-Making Division -- 2nd Update

16 sept. 2024, 21:16 UTC

Résultats

Tech Growth Is Slowing. These 6 Companies Could Still Shine. -- Barrons.com

16 sept. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 sept. 2024, 20:46 UTC

Actualités

Amazon Tells Workers to Return to Office Five Days a Week -- 2nd Update

16 sept. 2024, 20:34 UTC

Actualités

Intel CEO Lays Out New Steps to Cut Costs and Bolster Chip-Making Division -- Update

16 sept. 2024, 20:28 UTC

Actualités

Boeing Freezes Hiring, Delays Pay Raises as Strike Worsens Finances -- 2nd Update

16 sept. 2024, 20:19 UTC

Actualités

Dow Hits Record as Investors Bet on Bigger Fed Cut -- WSJ

16 sept. 2024, 20:07 UTC

Actualités

Intel CEO Lays Out New Steps to Cut Costs and Bolster Chip-Making Division -- WSJ

Comparaison

Variation de prix

Amarin Corp PLC ADR prévision

Objectif de Prix

By TipRanks

66.67% hausse

Prévisions sur 12 Mois

Moyen 1 USD 66.67%

Haut 1 USD

Bas 1 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Vente

2 ratings

Achat

Maintien

Vente

Basé sur 2 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

0.5818 / 0.6095Support & Résistance

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

There is one bearish event.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Amarin Corp PLC ADR

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.